# Tafenoquine Thorough QTc Study in Healthy Subjects

> **NCT01928914** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 260 (actual)

## Conditions studied

- Malaria, Vivax

## Interventions

- **DRUG:** Tafenoquine 300mg
- **DRUG:** Tafenoquine 600mg
- **DRUG:** Tafenoquine 1200mg
- **DRUG:** moxifloxacin
- **DRUG:** Placebo for Tafenoquine
- **DRUG:** Placebo for moxifloxaxin

## Key facts

- **NCT ID:** NCT01928914
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-26
- **Primary completion:** 2012-06-04
- **Final completion:** 2012-06-04
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928914, "Tafenoquine Thorough QTc Study in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01928914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*